Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy ; volume:14 ; number:1 ; day:18 ; month:4 ; year:2024 ; pages:1-9 ; date:12.2024
Scientific reports ; 14, Heft 1 (18.4.2024), 1-9, 12.2024
- Urheber
-
Brun, Sinne Søberg
Hansen, Torben Frøstrup
Wen, Sara Witting Christensen
Nyhus, Christa Haugaard
Bertelsen, Lisbeth
Jakobsen, Anders
Hansen, Torben Schjødt
Nederby, Line
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-59791-0
- URN
-
urn:nbn:de:101:1-2406302124448.205565186604
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Brun, Sinne Søberg
- Hansen, Torben Frøstrup
- Wen, Sara Witting Christensen
- Nyhus, Christa Haugaard
- Bertelsen, Lisbeth
- Jakobsen, Anders
- Hansen, Torben Schjødt
- Nederby, Line
- SpringerLink (Online service)
Ähnliche Objekte (12)
Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
Author Correction: Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
Prognostic value of soluble programmed death-1 and soluble programmed death ligand-1 in severe traumatic brain injury patients
Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
Author Correction: Prognostic value of soluble programmed death-1 and soluble programmed death ligand-1 in severe traumatic brain injury patients
Metastatic Melanoma Treatment with Pembrolizumab after Hypersensitivity Reaction to Nivolumab: A Case Report
Fulminant Marginal Keratitis Induced by Atezolizumab, a Programmed Death Ligand 1 Inhibitor for Lung Cancer
Autoimmune Nebenwirkungen von Nivolumab, Ipilimumab und Pembrolizumab : Chancen und Risiken der Therapie mit Checkpoint-Inhibitoren
Pembrolizumab
Nivolumab plus ipilimumab versus nivolumab in individuals with treatment-naive programmed death-ligand 1 positive metastatic soft tissue sarcomas: a multicentre retrospective study
Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
Author Correction: Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
Prognostic value of soluble programmed death-1 and soluble programmed death ligand-1 in severe traumatic brain injury patients
Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
Author Correction: Prognostic value of soluble programmed death-1 and soluble programmed death ligand-1 in severe traumatic brain injury patients
Metastatic Melanoma Treatment with Pembrolizumab after Hypersensitivity Reaction to Nivolumab: A Case Report
Fulminant Marginal Keratitis Induced by Atezolizumab, a Programmed Death Ligand 1 Inhibitor for Lung Cancer
Autoimmune Nebenwirkungen von Nivolumab, Ipilimumab und Pembrolizumab : Chancen und Risiken der Therapie mit Checkpoint-Inhibitoren
Pembrolizumab
Nivolumab plus ipilimumab versus nivolumab in individuals with treatment-naive programmed death-ligand 1 positive metastatic soft tissue sarcomas: a multicentre retrospective study
Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
Author Correction: Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
Prognostic value of soluble programmed death-1 and soluble programmed death ligand-1 in severe traumatic brain injury patients
Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
Author Correction: Prognostic value of soluble programmed death-1 and soluble programmed death ligand-1 in severe traumatic brain injury patients
Metastatic Melanoma Treatment with Pembrolizumab after Hypersensitivity Reaction to Nivolumab: A Case Report
Fulminant Marginal Keratitis Induced by Atezolizumab, a Programmed Death Ligand 1 Inhibitor for Lung Cancer
Autoimmune Nebenwirkungen von Nivolumab, Ipilimumab und Pembrolizumab : Chancen und Risiken der Therapie mit Checkpoint-Inhibitoren
Pembrolizumab
Nivolumab plus ipilimumab versus nivolumab in individuals with treatment-naive programmed death-ligand 1 positive metastatic soft tissue sarcomas: a multicentre retrospective study